🇺🇸 FDA
Patent

US 11478517

Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof

granted A61KA61K2039/5254A61K2039/5258

Quick answer

US patent 11478517 (Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof) held by The Board of Regents of the University of Texas System expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/5254, A61K2039/5258, A61K2039/543, A61K35/76